GLUCOSET AS

Their core work

GlucoSet AS is a Norwegian medical technology SME developing a microsensor for continuous arterial blood glucose monitoring. Their core technology uses boronic acid hydrogel sensing to measure glucose levels directly in the bloodstream, targeting clinical settings where real-time, accurate glucose data is critical. The company progressed from feasibility (SME Phase 1) to full development (SME Phase 2 with €2.4M funding), indicating a product moving toward clinical validation. They also have connections to Raman spectroscopy through collaborative research, suggesting broader biosensing capabilities.

What they specialise in

How they've shifted over time

GlucoSet's H2020 journey shows a classic SME scale-up trajectory. They started in 2016 with a small feasibility study (€50K, SME Phase 1) to validate their boronic acid hydrogel glucose sensor concept, then secured a major €2.4M SME Phase 2 grant in 2018 to develop the full microsensor product. Their participation in the VISGEN project (Raman spectroscopy) suggests they expanded their sensing technology toolkit mid-journey, potentially integrating optical spectroscopy methods into their biosensor work.

GlucoSet is moving from research validation toward a market-ready implantable glucose monitoring device, likely approaching clinical trials and regulatory approval stages.

How they like to work

GlucoSet primarily leads its own projects (coordinator in 2 of 3), which is typical for a product-focused SME driving its own technology roadmap. With 20 partners across 7 countries, they build moderately sized consortia and are open to international collaboration. Their participation in the large VISGEN research network (MSCA-RISE) shows willingness to engage in fundamental research partnerships beyond their core product development.

GlucoSet has worked with 20 unique partners across 7 countries, indicating a well-connected European network for a small SME. Their partnerships span both applied product development (SME Instrument consortia) and fundamental research (MSCA mobility networks).

What sets them apart

GlucoSet occupies a specific niche: continuous arterial glucose monitoring using chemical hydrogel sensors, distinct from the dominant subcutaneous CGM market (Dexcom, Abbott). Their intravascular approach targets hospital and intensive care settings where arterial accuracy matters most. The combination of chemical sensing (boronic acid hydrogels) and optical methods (Raman spectroscopy exposure) gives them a dual-modality perspective that few small biosensor companies possess.

Highlights from their portfolio

• GlucoSet
  Their flagship SME Phase 2 project with €2.4M funding — represents the full product development push for their arterial glucose microsensor.
• VISGEN
  A large MSCA-RISE research network on visual genetics and Raman spectroscopy, connecting GlucoSet to fundamental life science research beyond their core medtech focus.